Clinical trial
A Study of Enzastaurin in Participants With Follicular Lymphoma
NCT00475644 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00475644 |
|---|---|
| Title | A Study of Enzastaurin in Participants With Follicular Lymphoma |
| Official title | A Phase 2 Study of Enzastaurin in Participants With Follicular Lymphoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular |
| Intervention type | Drug |
| Interventions | Enzastaurin |
| Enrollment | 66 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2012 |
| Completion | Dec 1, 2014 |
| First posted | May 21, 2007 |
| Last update posted | Nov 5, 2018 |
| Countries | Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: